TTP startcodon

TTP plc to support life science and healthcare start-ups through partnership with Start Codon

TTP will provide entrepreneurs with mentoring and tech consultancy, to accelerate product development and commercialisation Agreement underlines TTP’s commitment to sharing knowledge and experience with innovative start-ups. TTP to deliver virtual seminar on 17 September as part of Start Codon and Cancer Research UK’s Entrepreneurial Training Scheme

Cambridge, UK, 03 September 2020: TTP plc (TTP), a leading independent technology and product development company, has today announced a new partnership with Start Codon, the life science and healthcare business accelerator. The collaboration aims to strengthen Start Codon’s support for life science and healthcare start-ups, with TTP providing technical consultancy and advice, leveraging TTP’s expertise to fast-track technology development and commercialisation. TTP will be delivering a virtual seminar on 17 September focussing on product development and commercialisation, as part of Start Codon and Cancer Research UK’s Entrepreneurial Training Scheme.

Start Codon aims to identify and recruit high-potential life science and healthcare companies from across the UK and beyond, provide seed-funding, and leverage the world-class resources of the Cambridge Cluster to reduce risk and prepare for a successful Series A fundraise. Under the terms of the partnership, Start Codon cohort companies will receive technology consultancy from TTP via one- to-one meetings and networking events throughout Start Codon’s six month ‘programme cycles.’ Both partners have committed to using their complementary networks and knowledge-base to co-host conferences and talks. Start Codon will promote TTP to their portfolio, thus helping TTP to connect with potential collaborators.

Dr Michelle Griffin, Clinical Innovator at TTP, said: “We are delighted to be working with Start Codon to help support their talented network. This partnership allows Start Codon and its cohort companies to tap into our experience in developing products and services that deliver recurrent successful clinical, scientific and financial outcomes.”

Dr Jason Mellad, CEO of Start Codon, said: “Product development plays a critical role in the growth of new companies. Having insight from TTP – who are recognised thought-leaders and experts in the life science and healthcare space – will strengthen our programme offering from this perspective, so we can help more companies translate their innovations into the clinic.”

Early stage start-up companies in the life sciences and healthcare space are invited to apply to the Start Codon accelerator programme via https://startcodon.co/application-form.

For further information on the Entrepreneurial Training Scheme, please visit https://startcodon.co/cruk " class="redactor-autoparser-object">https://startcodon.co/cruk&nbs...;or to register for the virtual seminar, please click here.

ENDS

Notes to Editors

Dr Michelle Griffin Clinical Innovator TTP plc

Dr Jason Mellad CEO
Start Codon

For high-resolution images please contact lorna.cuddon@zymecommunications.com

For further information, please contact:

Zyme Communications

Lorna Cuddon
Tel: +44 (0)7811 996 942
Email: lorna.cuddon@zymecommunications.com

TTP plc

Sam Zacherino
Tel: +44763262626 Email: press@ttp.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.

About TTP plc www.ttp.com

TTP is an independent technology company where scientists and engineers collaborate to invent,

design and develop new products and technologies. Working across a wide spectrum of industries

including health, telecoms, industrials and consumer, TTP creates breakthrough solutions that bring

strong commercial value to clients and the benefits of technology to all.

Follow TTP on Twitter @ttp_plc and LinkedIn @TTP plc

About Start Codon https://startcodon.co/
Start Codon is a new model of venture builder, and the first in Cambridge, UK to provide companies with a combination of seed funding, facilities, mentoring and access to a dedicated team and network of industry leading contacts. Founding investors in Start Codon include Cambridge Innovation Capital, the Babraham Research Campus through Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.

Founded to identify ideas that have the potential to impact the diagnosis, prevention and/or treatment of disease, and support their path to successful funding, Start Codon aims to revolutionise the way life science and healthcare innovation is commercialised by reducing risk in investment opportunities and developing companies in the Cambridge, UK cluster that are built to succeed globally.

Follow Start Codon on Twitter @StartCodon and LinkedIn @Start Codon